Gruppo Lepetit S.p.a.

The Dow Chemical Company

Gnosis Spa

Gnosis Srl

Simona Daly

Roberto Xaiz

Hermes Pagani

Alberto Benedetti

Carolina Coronelli

Francesco Parenti

Bruno Cavalleri

Giorgio Tamoni

Giancarlo Volpe

Giorgio Pirali

Giovanni Cassani

Maria Grandi

Matilde Manzoni

Maria Rosa Bardone

Marina Nichele

Manuela Rollini

Enrico Giuseppe Roberto Berardi

Richard White

Giorgion Tamoni

Manuela Paternoster

Simona Riboldi

A process for the preparation of vitamin K2 (MK-7) comprising the culture ofmutant strain GN13/72-DSM 17766 deposited on Dec. 5, 2005 at the DSMZ.

Process for the preparation of vitamin K2

There is disclosed a fermentation process for producing glutathione which comprises (a) the obtainment of a biomass pre-culture by pre-cultivating, in aerobic conditions, a strain of a glutathione producing yeast wherein the glutathione content per biomass unit is higher than 1.2% w/w; (b) the cultivation, in aerobic conditions, of the resulting biomass pre-culture such that the resulting biomass density is higher than 50 g/l; (c) the activation of the cultured biomass; and (d) the recovery of the cultured biomass, extracting glutathione at a pH equal to or lower than 6 and purifying the resulting glutathione. The process allows to obtain glutathione with high yields and relatively low costs.

Process for producing glutathione

New antibiotic substances arbitrarily designated M 9026 complex, antibiotic M 9026 factor 1, antibiotic M 9026 factor 2, and antibiotic M 9026 factor 3, produced by fermentation of a strain of the Micromonospora genus. The antibiotics of the invention are antimicrobial and antitumor agents.

Antimicrobial and antitumor antibiotic M 9026 and its pure individual

The present invention relates to a glycopeptide antibiotic arbitrarily designated as A/16686 antibiotic, and to its physiologically-acceptable acid addition salts. Antibiotic A/16686 free base, and its acid addition salts are antibacterial agents, especially active against grampositive microorganisms. The process for producing antibiotic A/16686 by culturing a novel strain of the actinoplanes genus, designated as Actinoplanes sp. ATCC 33076, is a further object of the present invention.

Biologically pure culture of actinoplanes capable of producing

The present invention relates to a glycopeptide antibiotic arbitrarily designated as A/16686 antibiotic, and to its physiologically-acceptable acid addition salts. Antibiotic A/16686 free base, and its acid addition salts are antibacterial agents, especially active against grampositive microorganisms. The process for producing antibiotic A/16686 by culturing a novel strain of the Antinoplanes genus, designated as Actinoplanes sp. ATCC 33076, is a further object of the present invention.

Antibiotic A/16686 and process for preparation thereof

A biologically pure culture of Actinoplanes sarveparensis.

Biologically pure culture

A new antibiotic prepared from aerobic cultivation of Actinoplanes sarveparensis and a method for producing the same from a culture medium.

Antibiotic substance from Actinoplanes sarveparensis CBS 305.76

The novel antibiotic, lipiarmycin, is prepared by cultivating Actinoplanes deccanensis A/10655, ATCC 21983, under aerobic conditions in a fermentation broth, from which it is then recovered.

Lipiarmycin and its preparation

Antibiotic activities produced by a variety of Streptosporangium vulgare named Streptosporangium vulgare var. antibioticum var. nov. ATCC 21906. The antibiotic complex contains at least the active fractions named A, B and C.

Growing community of inventors

Milan, Italy

Hermes Pagani